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Abstract
Galactosialidosis is an autosomal recessive lysosomal storage disease caused by the combined deficiency of lysosomal
β-galactosidase and neuraminidase due to a defect in the protective protein/cathepsin A. Patients present with various
clinical manifestations and are classified into three types according to the age of onset: the early infantile type, the late
infantile type, and the juvenile/adult type. We report a Japanese female case of juvenile/adult type galactosialidosis.
Clinically, she presented with short stature, coarse facies, angiokeratoma, remarkable action myoclonus, and cerebellar
ataxia. The patient was diagnosed with galactosialidosis with confirmation of impaired β-galactosidase and
neuraminidase function in cultured skin fibroblasts. Sanger sequencing for CTSA identified a compound heterozygous
mutation consisting of NM_00308.3(CTSA):c.746+ 3A>G and c.655-1G>A. Additional analysis of her mother’s DNA
sequence indicated that the former mutation originated from her mother, and therefore the latter was estimated to be
from the father or was a de novo mutation. Both mutations are considered pathogenic owing to possible splicing
abnormalities. One of them (c.655-1G>A) is novel because it has never been reported previously.
Galactosialidosis (GS, OMIM #256540) is an autosomal
recessive lysosomal storage disorder (LSD) caused by a
primary defect of protective protein/cathepsin A (PPCA)
and/or a secondary defect of components of the lysosomal
multienzyme complex (LMC), which includes the two
glycosidases, β-galactosidase (β-Gal) and neuraminidase-1
(NEU1)1,2. PPCA is also designated as cathepsin A
(CTSA) and is one of the serine carboxypeptidase-type
enzymes that protects and stabilizes the LMC from lyso-
somal degradation3. Until now, 35 mutations in the CTSA
gene in patients with GS have been published (Supple-
mental Table). In these patients, almost all mutations
belonged to the early infantile and late infantile types.
Most juvenile/adult type cases are of Japanese origin4,5.
Although the majority of GS cases belong to the juvenile/
adult type, there are very few case reports with a muta-
tion, let alone heterozygous mutations. Patients with
juvenile/adult type GS present broad clinical symptoms:
coarse facies, vertebral changes, cherry-red spots and
neurological complications, such as myoclonus, cerebellar
ataxia, epilepsy, and cognitive impairment. In general,
hepatosplenomegaly and angiokeratoma, typical mani-
festations in GS, are often absent in juvenile/adult type
cases. Even though the prognosis is not as poor as those of
the early infantile and late infantile types6,7, there is no
definitive treatment.
A 23-year-old Japanese female was admitted for hand
tremors and unsteadiness on her feet. Her parents were
nonconsanguineous. Though she had been admitted to a
pediatric clinic to investigate the cause of her short stature
when she was 10 years old, no examinations indicated
hormonal abnormalities. Her mother had no abnormal
findings except for her short stature, and the patient could
not contact her father after her parents’ divorce. From the
age twenty, she presented with ataxia while walking and
had hand tremors. She had coarse facies (Fig. 1a), short
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stature (135 cm) and angiokeratoma (Fig. 1b) on her
extremities. Neurologically, she presented no weakness of
muscles and had normal deep tendon reflex but had
action myoclonus of the hands and cerebellar ataxia; her
scanning speech, nose-to-finger and heel-to-knee tests
were clumsy.
Neuropsychological assessments indicated that her
Wechsler adult intelligence scale (WAIS)-III intelligence
quotient (IQ) was 64 (verbal IQ 83, performance IQ 52),
and the Mini-Mental State Examination was 27/30. An
ophthalmologist found a cherry-red spot on her eye
ground (Fig. 1c). There was no abnormal data in general
blood and biochemistry tests, but vacuolation of lym-
phocytes (Fig. 1d) was observed. X-rays showed thoracic
and vertebral deformities, computed tomography scan
showed mild hepatosplenomegaly, and brain magnetic
resonance image displayed mild atrophy of cerebral and
cerebellar cortexes for her age (data not shown). Echo-
cardiography demonstrated moderate aortic and mitral
valve regurgitations. Electroencephalography did not
show any giant somatosensory evoked potential or C-
reflex.
Because of the cherry-red spot on her eye ground and
vacuolation of lymphocytes, we suspected that she had a
type of LSD. We tested urine catabolites but could not
find any accumulation of uronic acids. Next, we analyzed
the levels of 10 lysosomal enzymes: β-gal, α-galactosidase,
β-glucosidase, α-glucosidase, β-hexosaminidase A, α-
mannosidase, α-fucosidase, β-glucuronidase, and NEU.
The levels of β-gal and NEU in cultured skin fibroblasts
were 111.2 nmol/mg protein/h (normal 401 ± 184.8) and 0
(normal 25.0 ± 17.0), respectively, but those of the other 8
enzymes were in the normal range. She was diagnosed
with GS. Next, CTSA gene analysis was performed by
using the Sanger method, and a compound heterozygous
mutation was identified; NM_00308.3(CTSA):c.746+
3A>G and c.655-1G>A (Fig. 2). c.746+ 3A>G, which is
considered to cause splicing abnormalities, is a common
Fig. 1 Characteristic findings of our patient. a Facial features: coarse facies, large nose, depressed nasal bridge, hypertelorism, and micrognathia.
b Angiokeratoma of arm skin. c A cherry-red spot of the right eye ground in funduscopy. d Peripheral blood smear with May-Giemsa stain shows
vacuolation of a lymphocyte
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variant in Japanese GS patients as a homozygous pat-
tern8,9. Subsequent analysis for the sample from the
mother identified the c.746+ 3A>G variant. Thus, this
variant is confirmed to be inherited from the mother. On
the other hand, c.655-1G>A has never been reported
previously, indicating a novel variant. Because we could
not obtain a sample from the father, the origin of the
c.655-1G>A variant is unknown.
After diagnosis, we prescribed carbamazepine and clo-
nazepam, and her action myoclonus improved, but ataxia
remained as before. After this admission, we additionally
tested the levels of residual CTSA (acid carboxypeptidase)
activity: 37.7 nmol/mg protein/h (control 2,796). We
confirmed CTSA deficiency in cultured skin fibroblasts.
Reports about the mutations in CTSA, except in the
CpG islands10, have been relatively few even though the
CTSA gene is approximately 43,000 kb, includes 15 exons
and is thus larger than other human genes. The reason is
not clear, but difficulty in diagnosing GS clinically seems
to be relevant.
For the stability of LMC, CTSA plays a role as a
molecular chaperone protein. Then, CTSA matures and
stabilizes β-Gal with processing of its carboxy terminus
and promotes oligomerization and activation of
NEU16,11,12. In GS patients, sialylated oligosaccharides,
and glycopeptides accumulate in lysosomes of every
tissue, which causes various clinical manifestations, as in
this case. The patient presented with ataxia, which was
presumably caused by decreased cerebellar Purkinje
cells13,14, and the myoclonus was caused by a disturbance
in the sensorimotor cortex by way of the thalamic tract or
cerebellothalamic tract15 because of the abnormal accu-
mulation of sialylated oligosaccharides and glycopeptides.
The magnetic resonance image of the patient also indi-
cated mild atrophy of the cerebellar and cerebral cortexes
for her age.
Normally, CTSA acts as a serine carboxypeptidase,
deaminase, and esterase in the processing of bioactive
peptides substance P, oxytocin, and endothelin2,16 and in
the formation of elastic fibers on the cell membrane17.
Therefore, mutation of CTSA produces a variety of
complications in endothelial cells, heart, kidney, central
nervous system, and so on. The identified compound
heterozygous mutation NM_00308.3(CTSA):c.746+
3A>G & c.655-1G>A might be related to the remarkable
neurological manifestations the patient presented. The
c.746+ 3A>G variant has been reported by Shimmoto
et al.9 with juvenile/adult type cases of exon 7 skipping9,
and the single-nucleotide variant was evaluated as
pathogenic by the Clin Var and HGMD® databases. c.655-
1G>A is also located next to the canonical splice site:





Fig. 2 Direct sequencing of CTSA gene exon 7 from normal control (upper), the patient (middle), and her mother (lower). IVS7,+3A>G
(c.746+ 3A>G) was inherited from the mother8,9. Neither we nor the patient could contact her father
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exon 7. According to the ACMG standards and guide-
lines18, the c.655-1G>A is also considered pathogenic,
although functional studies have not been performed. By
analyzing the patient’s mother’s DNA sequence, we could
confirm that c.746+ 3A>G originated from the mother;
therefore, we determined that c.655-1G>A was from the
father or was a de novo variant. A certain study reported
that the amounts of residual acid carboxypeptidase
activities did not correlate with clinical phenotypes, but
the enzyme deficiency is closely connected to the genetic
defect of protective protein, CTSA19. Therefore, it is
possible that the IVS7, +3A>G mutation of the CTSA
gene is one of the contributing factors to her short stature
because the mother was only a carrier without other
complications.
Some limitations exist in this study. First, we were not
able to confirm the heterozygosity with the father’s sam-
ple because he was unable to be located. Second, owing to
the sample condition, we did not obtain scientific evi-
dence that confirmed splicing abnormalities are caused by
c.655-1G>A. These problems will be our next research
topics.
We, as clinicians should observe each symptom care-
fully and treat it with the best supportive care. This
compound heterozygous mutation in the CTSA gene
would also be a new target for enzyme replacement
therapies and gene therapies such as bone marrow
transplantation using transgenic bone marrow cells
overexpressing the corrective enzymes14 or gene delivery
with a recombinant vector20. We hope these findings will
contribute to the elucidation of the pathogenesis and
treatment of GS.
HGV Database
The relevant data from this Data Report are hosted at the Human Genome
Variation Database at https://doi.org/10.6084/m9.figshare.hgv.2573.
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